Routine statin treatment after acute coronary syndromes?

American Heart Journal

Volumn 143, Issue 6, 2002, Pages 940-942

  Acevedo, Monica ^a   Sprecher, Dennis L ^a   Lauer, Michael S ^a   Francis, Gary ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DECISION MAKING; EDITORIAL; HEART PROTECTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; TREATMENT INDICATION;

EID: 0036085643     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.122284     Document Type: Article

References (33)

1. 27th Bethesda conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease
2. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada
3. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries
4. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality
5. Improved treatment of Coronary Heart disease by implementation of a cardiac hospitalization Atherosclerosis Management Program (CHAMP)
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
7. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
8. Beneficial effects of pravastatin (+/- cholestiramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study)
9. The short-term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction
10. Effect of lipid lowering therapy on early mortality after acute coronary syndromes: An observational study
11. Early statin treatment following acute myocardial infarction and 1-year survival
12. Heart Protection Study (HPS)
13. Early determination of serum lipids and apolipoproteins in acute myocardial infarction: Possibility for immediate intervention
14. Myocardial injury: The acute phase response and lipoprotein metabolism
15. When to start cholesterol-lowering therapy in patients with coronary heart disease: A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
16. Strategies for implementing lipid-lowering therapy: Pharmacy-based approach
17. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative
18. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
19. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
20. Fluvastatin in acute myocardial infarction: Effects on early and late ischemia events: The FLORIDA trial
21. Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: Results of MITRA 2
22. Role of statins in patients with acute coronary syndromes
23. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality
24. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIMI 16
25. Early statin use ofter acute coronary syndromes (ACS) and outcomes at 90 days
26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
27. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and recurrent events trial investigators
28. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 Update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
29. PIA2 polymorphism and efficacy of aspirin
30. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients
31. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina)
32. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3
33. A case-management system for coronary risk factor modification after acute myocardial infarction